Memphasys Limited (MEM.AX)
AUD 0.01
(-14.29%)
AUD 0.01
(-14.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -3.3 Million AUD | -44.23% |
| 2023 | -2.36 Million AUD | -16.92% |
| 2022 | -1.38 Million AUD | -80.17% |
| 2021 | -1.13 Million AUD | -34.59% |
| 2020 | -869.05 Thousand AUD | 0.88% |
| 2019 | -988.32 Thousand AUD | 6.28% |
| 2018 | -103.21 Thousand AUD | 45.09% |
| 2017 | -1.74 Million AUD | -19.04% |
| 2016 | -1.82 Million AUD | -8.48% |
| 2015 | -1.61 Million AUD | -51.58% |
| 2014 | -472.97 Thousand AUD | 53.06% |
| 2013 | -1.96 Million AUD | -49.72% |
| 2012 | -5.76 Million AUD | -267862.96% |
| 2011 | -5.43 Million AUD | -99.98% |
| 2010 | 3.77 Million AUD | 443.11% |
| 2009 | -2.13 Million AUD | 81.04% |
| 2008 | -4.81 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.16 Million AUD | 0.0% |
| 2024 FY | - AUD | -49.68% |
| 2024 Q4 | -2.35 Million AUD | 0.0% |
| 2023 Q2 | -1.19 Million AUD | 0.0% |
| 2023 Q4 | -1.82 Million AUD | 0.0% |
| 2023 FY | - AUD | -16.92% |
| 2022 Q2 | -738.28 Thousand AUD | 0.0% |
| 2022 Q4 | -1.22 Million AUD | 0.0% |
| 2022 FY | - AUD | -80.17% |
| 2021 Q2 | -681.2 Thousand AUD | 0.0% |
| 2021 FY | - AUD | -34.59% |
| 2021 Q4 | -760.82 Thousand AUD | 0.0% |
| 2020 Q4 | -338.02 Thousand AUD | 0.0% |
| 2020 Q2 | -727.48 Thousand AUD | 0.0% |
| 2020 FY | - AUD | 0.88% |
| 2019 Q2 | -581.18 Thousand AUD | 0.0% |
| 2019 Q4 | -493.74 Thousand AUD | 0.0% |
| 2019 FY | - AUD | 6.28% |
| 2018 FY | - AUD | 45.09% |
| 2018 Q2 | -706.89 Thousand AUD | 0.0% |
| 2018 Q4 | -440.04 Thousand AUD | 0.0% |
| 2017 Q2 | -846.8 Thousand AUD | 0.0% |
| 2017 FY | - AUD | -19.04% |
| 2016 FY | - AUD | -8.48% |
| 2016 Q2 | -1.08 Million AUD | 0.0% |
| 2015 Q2 | -969.21 Thousand AUD | 0.0% |
| 2015 FY | - AUD | -51.58% |
| 2014 Q1 | -296.45 Thousand AUD | 0.0% |
| 2014 FY | - AUD | 53.06% |
| 2014 Q4 | 166.00 AUD | 100.02% |
| 2014 Q3 | -805.42 Thousand AUD | 21.43% |
| 2014 Q2 | -1.02 Million AUD | -245.78% |
| 2013 Q3 | -296.45 Thousand AUD | 56.34% |
| 2013 FY | - AUD | -49.72% |
| 2013 Q4 | -296.45 Thousand AUD | 0.0% |
| 2013 Q2 | -679 Thousand AUD | 54.33% |
| 2013 Q1 | -1.48 Million AUD | 0.0% |
| 2012 Q2 | -1.48 Million AUD | -2.3% |
| 2012 Q3 | -1.48 Million AUD | 0.0% |
| 2012 Q4 | -1.48 Million AUD | 0.0% |
| 2012 FY | - AUD | -267862.96% |
| 2012 Q1 | -1.45 Million AUD | 0.0% |
| 2011 FY | - AUD | -99.98% |
| 2011 Q1 | 943.22 Thousand AUD | 0.0% |
| 2011 Q3 | -1.45 Million AUD | 0.0% |
| 2011 Q4 | -1.45 Million AUD | 0.0% |
| 2011 Q2 | -1.45 Million AUD | -254.07% |
| 2010 Q2 | 943.22 Thousand AUD | 276.79% |
| 2010 Q3 | 943.22 Thousand AUD | 0.0% |
| 2010 Q1 | -533.52 Thousand AUD | 0.0% |
| 2010 Q4 | 943.22 Thousand AUD | 0.0% |
| 2010 FY | - AUD | 443.11% |
| 2009 Q1 | -1.2 Million AUD | 0.0% |
| 2009 Q4 | -533.52 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 81.04% |
| 2009 Q3 | -533.52 Thousand AUD | 0.0% |
| 2009 Q2 | -533.52 Thousand AUD | 55.69% |
| 2008 Q3 | -1.2 Million AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | -1.2 Million AUD | 0.0% |
| 2008 Q2 | -1.2 Million AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | 37.622% |
| Biome Australia Limited | -1.57 Million AUD | -109.581% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 92.71% |
| Biotron Limited | -5.04 Million AUD | 34.371% |
| Acrux Limited | -7.93 Million AUD | 58.294% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 83.099% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 76.237% |
| BTC Health Limited | 1.05 Million AUD | 413.443% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 70.728% |
| CSL Limited | 4.73 Billion AUD | 100.07% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 92.591% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 106.378% |
| Immutep Limited | -42.87 Million AUD | 92.285% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 101.66% |
| Noxopharm Limited | -5.94 Million AUD | 44.366% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 53.968% |
| Race Oncology Limited | -14.2 Million AUD | 76.712% |
| Starpharma Holdings Limited | -12.57 Million AUD | 73.7% |
| Tissue Repair Ltd | -5.77 Million AUD | 42.723% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 131.88% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -127.075% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -11.184% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 90.923% |
| Patrys Limited | -3.49 Million AUD | 5.281% |
| Orthocell Limited | -11.68 Million AUD | 71.683% |
| Imugene Limited | -147.97 Million AUD | 97.765% |
| PYC Therapeutics Limited | -38.11 Million AUD | 91.322% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 58.063% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 66.757% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 62.553% |
| Nanollose Limited | -1.14 Million AUD | -188.154% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -359.124% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -84.142% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 27.456% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -17.373% |
| Nyrada Inc. | -4.59 Million AUD | 28.034% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 114.403% |
| Dimerix Limited | -24.95 Million AUD | 86.747% |
| PharmAust Limited | -9.45 Million AUD | 65.004% |
| Hexima Limited | -995.54 Thousand AUD | -232.253% |
| AnteoTech Limited | -11.57 Million AUD | 71.414% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 94.875% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 84.51% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -2.011% |
| Actinogen Medical Limited | -12.92 Million AUD | 74.401% |
| Immuron Limited | -6.19 Million AUD | 46.584% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -74.312% |